ANNX Latest Press Releases

-- October 28, 2026 --

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial Globe Newswire 8:00 AM

-- October 16, 2026 --

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:34 PM

-- September 24, 2026 --

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting Globe Newswire 8:00 AM

-- September 16, 2026 --

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 2, 2026 --

Annexon to Participate in Upcoming September Investor Conferences Globe Newswire 8:00 AM

-- August 17, 2026 --

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 12, 2026 --

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Globe Newswire 6:05 AM

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study Globe Newswire 6:00 AM

-- August 10, 2026 --

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors Globe Newswire 4:05 PM

-- August 6, 2026 --

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week Globe Newswire 8:00 AM

-- July 30, 2026 --

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance Globe Newswire 4:01 PM

-- July 16, 2026 --

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 14, 2026 --

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 Globe Newswire 4:05 PM

-- June 16, 2026 --

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes